The Expanding Presbyopia Landscape

Show Description +

With more than 120 million Americans, and nearly 2 billion people worldwide, suffering from presbyopia, Preeya Gupta, MD, sees a substantial need for a more diverse portfolio of presbyopia­ correcting options. As the number of patients affected by presbyopia grows, Dr. Gupta suggests that a novel presbyopia therapeutic present a perfect treatment option for patients to consider.

Posted: 11/23/2021

The Expanding Presbyopia Landscape

With more than 120 million Americans, and nearly 2 billion people worldwide, suffering from presbyopia, Preeya Gupta, MD, sees a substantial need for a more diverse portfolio of presbyopia­ correcting options. As the number of patients affected by presbyopia grows, Dr. Gupta suggests that a novel presbyopia therapeutic present a perfect treatment option for patients to consider.

Posted: 11/23/2021

About Orasis Pharmaceuticals

ORASIS (OR-uh-sis) Pharmaceuticals is an emerging ophthalmic pharmaceutical company, with offices in the US and Israel, focused on developing an innovative solution for the treatment of presbyopia symptoms. Orasis’ novel proprietary formulation of low dose pilocarpine and a proprietary vehicle was purposefully designed with the patient in mind to achieve an optimal balance among efficacy, safety, and comfort.

The name Orasis has its roots in the Greek language, where it carries a literal translation of “good vision or sight.” Beyond this, however, as good vision in its positive mental/philosophical meaning — and this speaks to our aspiration as a company to develop pharmaceutical drugs that improve vision and quality of life for millions of people around the world.

Visit us online: orasis-pharma.com

Contact Us

Follow Orasis Pharmaceuticals